3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Status
Suspended
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Pancreatic Neoplasms
7
Breast Neoplasms
7
Colorectal Neoplasms
6
Stomach Neoplasms
5
Neoplasms
5
Sarcoma
3
Precision Cell Immunotherapy
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Mesothelioma, Malignant
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Hodgkin Disease
3
Glioblastoma
3
Esophageal Neoplasms
3
Wilms Tumor
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Mesothelioma
2
Melanoma
2
Lymphoma
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Ovarian Epithelial
2
Virus Diseases
1
Interventions
Peripheral Blood Stem Cell Transplantation
5
Cyclophosphamide
5
romidepsin
4
pembrolizumab
4
Lenalidomide
4
Etoposide
4
10-propargyl-10-deazaaminopterin
4
Rituximab
3
fludarabine phosphate
2
fludarabine
2
durvalumab
2
carmustine, poliferprosan 20 drug combination
2
Vincristine
2
Prednisone
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Melphalan
2
Gemcitabine
2
Doxorubicin
2
Depsipeptides
2
Cytarabine
2
Carmustine
2
Bendamustine Hydrochloride
2
AFM13
2
veliparib
1
thymoglobulin
1
tenalisib
1
temsirolimus
1
prednylidene
1
mogamulizumab
1
forodesine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, T-Cell
×
Drug Therapy
×
Clear all
NCT05138458
2023-11-13
IMAGINE
Myeloid Therapeutics
Phase 1/2
Suspended
40 enrolled